Haute MD is a curated directory of board-certified physicians across six specialties, independently reviewed and editorially featured by Haute Living.

How are Haute MD doctors selected?

Every Haute MD physician is editorially vetted by the Haute Living editorial team based on credentials, patient outcomes, and professional reputation.

What specialties does Haute MD cover?

Haute MD features physicians in Plastic Surgery, Facial Plastic Surgery, Cosmetic Dentistry, Dermatology, Fertility, and Concierge Medicine.

glp1-ozempic

Ozempic vs. Wegovy: Same Drug, Different Uses

Last reviewed: May 2026 · Haute MD Editorial Team

Ozempic and Wegovy contain the same active ingredient — semaglutide — but are FDA-approved for different indications at different doses, have different insurance coverage profiles, and occupy different positions in the treatment of metabolic disease. Understanding the distinction matters for patients trying to access semaglutide for weight management and for physicians navigating insurance coverage and appropriate prescribing.

The key differences explained

Ozempic (semaglutide 0.5mg, 1mg, or 2mg weekly injection) — FDA-approved for type 2 diabetes management. Also reduces cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Not FDA-approved for weight loss without diabetes, though it produces significant weight loss at therapeutic doses. Insurance typically covers Ozempic for diabetic patients. Wegovy (semaglutide 2.4mg weekly injection) — FDA-approved for chronic weight management in adults with BMI 30+ or BMI 27+ with weight-related comorbidity, with or without diabetes. The 2.4mg dose produces average 15-17% body weight loss. Insurance coverage is variable and inconsistently covers Wegovy even in patients who qualify.

Why patients end up on Ozempic for weight loss

Wegovy's irregular supply (shortages throughout 2022-2024), inconsistent insurance coverage, and higher list price have led many patients and prescribers to use Ozempic off-label for weight loss — at the 0.5-2mg doses approved for diabetes. Off-label Ozempic for weight loss is legal physician prescribing practice. The weight loss at Ozempic doses (0.5-2mg) is real but somewhat less than at Wegovy's 2.4mg — approximately 5-10% vs. 15-17% at maximum dose. Patients who can access Wegovy (either through insurance coverage or affordable out-of-pocket cost) produce better weight loss outcomes at the approved 2.4mg dose.

Insurance considerations and access strategies

Ozempic for diabetes — typically covered by commercial insurance and Medicare Part D for patients with type 2 diabetes diagnosis. Wegovy for obesity — covered by a growing but still inconsistent set of commercial plans; not currently covered by traditional Medicare (though legislation is pending). Employer-sponsored plans increasingly add Wegovy coverage as evidence of cardiovascular benefit mounts. Novo Nordisk (manufacturer) offers savings cards that reduce cost for commercially insured patients who meet criteria. Compounded semaglutide — during FDA shortage periods, compounding pharmacies produced semaglutide at dramatically lower cost; the FDA has ended the shortage designation for semaglutide as of early 2025, making compounded semaglutide legally questionable going forward.

Frequently Asked Questions

Can I take Ozempic for weight loss if I don't have diabetes?

Prescribing Ozempic off-label for weight loss in patients without diabetes is legal physician practice and is widely done. However, insurance will not cover Ozempic for a non-diabetic patient. At-risk cash prices for Ozempic without insurance run $800-$1,000/month. Wegovy is the FDA-approved option for non-diabetic weight management and is the appropriate label indication for non-diabetic patients.

Is there a difference in how Ozempic and Wegovy work?

No — both contain semaglutide and work identically through GLP-1 receptor agonism. The difference is dose. Higher dose produces greater weight loss and greater GI side effects. The 2.4mg Wegovy dose produces approximately 15-17% body weight loss vs. approximately 5-10% at the 1mg Ozempic dose.

What will Ozempic cost me without insurance?

Ozempic lists at approximately $900-$1,000/month at US pharmacies without insurance. Novo Nordisk's savings card reduces cost to $25/month for eligible commercially insured patients. Without insurance and without savings card, it is unaffordable for most patients long-term. GoodRx and similar discount cards provide modest savings. International pharmacy options (Canada, Mexico) offer dramatically lower prices but require careful sourcing.

What is the difference between Ozempic and Mounjaro?

Ozempic contains semaglutide — a GLP-1 receptor agonist. Mounjaro (tirzepatide) acts on both GLP-1 and GIP receptors — a dual agonist. Mounjaro (approved for T2D) and its obesity-specific counterpart Zepbound produce greater weight loss (20-22% average) than semaglutide (15-17%). Tirzepatide also has a favorable cardiovascular outcomes trial profile. For patients who can access either, tirzepatide generally produces superior weight loss outcomes.

Get Help Now